布洛芬治疗极低出生体重早产儿动脉导管未闭的疗效观察

摘要

目的 观察布洛芬治疗极低出生体重早产儿动脉导管未闭(PDA)的临床疗效及安全性.方法 46例PDA早产患儿随机分为观察组和对照组各23例,对照组给予吲哚美辛口服,首剂0.2 mg/kg,后改为0.1 mg/kg,每次间隔12h,共用药3次；观察组给予布洛芬混悬液口服,首剂10 mg/kg,在24h和48 h后分别给予5 mg/kg;比较两组患儿的疗效及不良反应.结果 观察组患儿的总有效率为95.7％,对照组为91.3％,两组比较差异无统计学意义(x2=0.357,P＞0.05)；两组治疗过程中均有不良反应发生,观察组少尿、肾功能异常的发生率显著低于对照组(P＜0.05),而胃肠道反应、脑室内出血等的发生率差异无统计学意义(P＞0.05).结论 布洛芬治疗极低出生体重早产儿动脉导管未闭的具有良好的疗效,且不良反应少,安全性好,值得在临床推广使用.%Objective To observe the clinical efficacy of ibuprofen in the treatment of patent ductus arteriosus (PDA) in very low birth weight premature infants. Methods Forty-six premature infants were randomly divided into the study group and the control group, with 23 cases in each group. Patients in the control group were treated with indometacin 0.2 mg/kg and then 0.1 mg/kg twice at an interval of 12 h. Patients in the study group was given ibuprofen suspension 10 mg/kg and then 5 mg/kg after 24 h and 48 h. The clinical efficacy and adverse reactions were compared between the two groups. Results The total effective rate was 95.7% in the study group and 91.3% in the control group, with no statistically significant difference between the two groups (χ2=0357, P>0.05). The incidences of ol-iguria and renal dysfunction in the study group were significantly lower than those in the control group (P<0.05). The incidences of gastrointestinal side effects and intraventricular hemorrhage showed no statistically significant difference between the two groups (P>0.05). Conclusion The clinical efficacy of ibuprofen in the treatment of PDA in very low birth weight premature infants is satisfactory and safe, which is worthy of extension in clinical practice.